Topigen Pharmaceuticals Inc. Reports Phase 2 Results of TPI ASM8 in Asthma Patients
1/9/2009 10:27:09 AM
More...
|
Topigen Pharmaceuticals Inc. Completes Formation of New Management Team With the Appointment of Robert Boisjoli as Chief Financial Officer
1/9/2009 10:15:58 AM
More...
|
Topigen Pharmaceuticals Inc. Moves Novel Inhaled PDE Inhibitor, TPI 1100, Into Clinical Development for COPD
12/23/2008 9:44:08 AM
More...
|
Topigen Pharmaceuticals Inc. To Present At Two Upcoming Medical Conferences
9/29/2008 12:17:16 PM
More...
|
Topigen Pharmaceuticals Inc. Appoints Mark Parry-Billings, Ph.D., as Chief Executive Officer
8/14/2008 7:13:06 AM
More...
|
Topigen Pharmaceuticals Inc. Completes Enrollment of Phase II Clinical Study of TPI ASM8 in Asthma
7/23/2008 8:25:59 AM
More...
|
Topigen Pharmaceuticals Inc. Appoints Jeremy Curnock Cook to Its Board of Directors
6/3/2008 10:32:06 AM
More...
|
Topigen Pharmaceuticals Inc. Announces Management Changes; Search for New CEO and CFO Begins
3/5/2008 3:55:23 PM
More...
|
Topigen Pharmaceuticals Inc. Initiates European Phase 2 Clinical Study of TPI ASM8 in Patients With Asthma
1/29/2008 10:05:11 AM
More...
|
Topigen Pharmaceuticals Inc. to Participate in BMO and RBC Healthcare Conferences
11/29/2007 1:44:31 PM
More...
|
|